CTMX - CytomX Therapeutics, Inc. News

Guggenheim Maintains Buy on CytomX Therapeutics, Lowers Price Target to $14

Guggenheim analyst Michael Schmidt maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and low

CytomX Therapeutics, Inc. (CTMX) Q2 2026 Earnings Call Transcript

marketbeat.com

CytomX Therapeutics Q2 Earnings Call Highlights

CytomX Therapeutics NASDAQ: CTMX said its second-quarter focus remained on advancing Varseta-M, an E

zacks.com

CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates

CytomX Therapeutics (CTMX) came out with a quarterly loss of $0.09 per share versus the Zacks Consen

CytomX Therapeutics Q2 EPS $(0.09) Beats $(0.11) Estimate, Sales $1.418M Miss $12.308M Estimate

CytomX Therapeutics (NASDAQ:CTMX) reported quarterly losses of $(0.09) per share which beat the anal

CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update

Varsetatug masetecan (“Varseta-M”) Program: - Phase 1 monotherapy update in advanced colorectal canc

CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CT

CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026

SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CT

defenseworld.net

ADAR1 Capital Management LLC Sells 872,579 Shares of CytomX Therapeutics, Inc. $CTMX

ADAR1 Capital Management LLC reduced its position in CytomX Therapeutics, Inc. (NASDAQ: CTMX) by 20.

CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors

SOUTH SAN FRANCISCO, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CT

zacks.com

CytomX Therapeutics (CTMX) Upgraded to Buy: Here's Why

CytomX Therapeutics (CTMX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism a

CytomX Therapeutics, Inc. (CTMX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference

CytomX Expands Collaboration And Licensing Agreement With Regeneron To Create Conditionally-Activate

- Expanded collaboration builds upon research momentum in developing next-generation bispecific immu

CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Condit

- Expanded collaboration builds upon research momentum in developing next-generation bispecific immu

CytomX Therapeutics: Cashed Up With Catalysts Ahead

In March, CTMX showcased Varseta-M's potential in late-line metastatic colorectal cancer, although t

CytomX Therapeutics to Present at Upcoming June Investor Conferences

SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTM

CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affa

SOUTH SAN FRANCISCO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTM

HC Wainwright & Co. Maintains Buy on CytomX Therapeutics, Lowers Price Target to $11

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains CytomX Therapeutics (NASDAQ:CTMX) wi

CytomX Therapeutics, Inc. (CTMX) Q1 2026 Earnings Call Transcript

zacks.com

CytomX Therapeutics (CTMX) Reports Q1 Loss, Beats Revenue Estimates

CytomX Therapeutics (CTMX) came out with a quarterly loss of $0.1 per share versus the Zacks Consens

CytomX Therapeutics Q1 EPS $(0.10) Beats $(0.20) Estimate, Sales $10.258M Beat $4.713M Estimate

CytomX Therapeutics (NASDAQ:CTMX) reported quarterly losses of $(0.10) per share which beat the anal

CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update

- Positive data announced from Phase 1 Dose Expansion Study of varsetatug masetecan (“Varseta-M”) Ep

CytomX Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026

SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: C

fool.com

Small Cap or Megacap: Which Healthcare Stock Is Right for You?

Healthcare companies with different market caps offer different rewards and challenges.

defenseworld.net

Stock Traders Buy High Volume of CytomX Therapeutics Put Options (NASDAQ:CTMX)

CytomX Therapeutics, Inc. (NASDAQ: CTMX - Get Free Report) was the target of some unusual options tr

Piper Sandler Maintains Overweight on CytomX Therapeutics, Raises Price Target to $12

Piper Sandler analyst Joseph Catanzaro maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overwei

12 Health Care Stocks Moving In Thursday's Intraday Session

Barclays Maintains Overweight on CytomX Therapeutics, Raises Price Target to $16

Barclays analyst Etzer Darout maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overweight and r

Jefferies Maintains Buy on CytomX Therapeutics, Raises Price Target to $16

Jefferies analyst Roger Song maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and raises th

Why Is CytomX Therapeutics Stock Falling On Wednesday?

CytomX stock falls after $250 million share sale, even as new colorectal cancer data shows strong re

Guggenheim Maintains Buy on CytomX Therapeutics, Raises Price Target to $15

Guggenheim analyst Michael Schmidt maintains CytomX Therapeutics (NASDAQ:CTMX) with a Buy and rai

Wedbush Maintains Outperform on CytomX Therapeutics, Raises Price Target to $11

Wedbush analyst Robert Driscoll maintains CytomX Therapeutics (NASDAQ:CTMX) with a Outperform and

CytomX Therapeutics Files Prospectus For Potential Offerings Of Stock, Debt, Warrants And Units

Common StockPreferred StockDebt SecuritiesWarrantsUnitsWe may offer and sell the securities identifi

CytomX Therapeutics Announces Public Offering Of $250M In Stock And Pre-Funded Warrants

In addition, CytomX expects to grant the underwriters a 30-day option to purchase up to an additiona

12 Health Care Stocks Moving In Monday's Intraday Session

Mid-Cap CytomX Therapeutics' Colorectal Cancer Data Fuels Stock Rally

CytomX Therapeutics stock jumps in premarket trading after Phase 1 data for Varseta-M showed tumor r

HC Wainwright & Co. Maintains Buy on CytomX Therapeutics, Raises Price Target to $17

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains CytomX Therapeutics (NASDAQ:CTMX) wi

Crude Oil Down 4%; Dollar Tree Earnings Top Views

JP Morgan Upgrades CytomX Therapeutics to Overweight, Raises Price Target to $12

JP Morgan analyst Anupam Rama upgrades CytomX Therapeutics (NASDAQ:CTMX) from Neutral to Overweig

Nebius Group, CytomX Therapeutics, National Storage Affiliates Trust And Other Big Stocks Moving Hig

Dow Jones index up 500 points; Nebius Group NV shares rise 12.7% on AI agreement with Meta Platforms

12 Health Care Stocks Moving In Monday's Pre-Market Session

Market-Moving News for March 16th

NBIS: 17% | Nebius Announced 5-Year $12B AI Infrastructure Agreement With Meta To Provide Dedicated

Earnings Scheduled For March 16, 2026

CytomX Therapeutics Announces Phase 1 Expansion Data For EpCAM PROBODY ADC, Varseta-M In Late-Line M

- Confirmed response rates in expansion cohorts of 32% at 10 mg/kg Q3W dose and 20% at 8.6 mg/kg Q3W

CytomX Therapeutics Q4 EPS $(0.22) Misses $(0.09) Estimate, Sales $663.000K Miss $7.900M Estimate

CytomX Therapeutics (NASDAQ:CTMX) reported quarterly losses of $(0.22) per share which missed the an

CytomX Therapeutics Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's M

CytomX Therapeutics (CTMX) will release its Q4 earnings on March 16, with analysts expecting a loss

Where CytomX Therapeutics Stands With Analysts

Guggenheim Reiterates Buy on CytomX Therapeutics, Maintains $10 Price Target

Guggenheim analyst Michael Schmidt reiterates CytomX Therapeutics (NASDAQ:CTMX) with a Buy and ma

Cantor Fitzgerald Maintains Overweight on CytomX Therapeutics, Raises Price Target to $10

Cantor Fitzgerald analyst Olivia Brayer maintains CytomX Therapeutics (NASDAQ:CTMX) with a Overwe